Skip to main content

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

European Journal of Nuclear Medicine and Molecular Imaging volume 37, pages 1095–1105 (2010)Cite this article

Abstract

Purpose

Accurate staging of Hodgkin’s lymphoma (HL) is necessary in selecting appropriate treatment. Bone marrow trephine biopsy (BMB) is the standard procedure for depicting bone marrow involvement. BMB is invasive and explores a limited part of the bone marrow. 18F-FDG PET/CT is now widely used for assessing response to therapy in HL and a baseline study is obtained to improve accuracy. The aim of this retrospective analysis was to assess whether routine BMB remains necessary with concomitant 18F-FDG PET/CT.

Methods

Data from 83 patients (newly diagnosed HL) were reviewed. All patients had received contrast-enhanced CT, BMB and 18F-FDG PET/CT. Results of BMB were not available at the time of 18F-FDG PET/CT imaging.

Results

Seven patients had lymphomatous involvement on BMB. Four patients had bone involvement on conventional CT (two with negative BMB). All patients with bone marrow and/or bone lesions at conventional staging were also diagnosed on 18F-FDG PET/CT scan. PET/CT depicted FDG-avid bone/bone marrow foci in nine additional patients. Four of them had only one or two foci, while the other had multiple foci. However, the iliac crest, site of the BMB, was not involved on 18F-FDG PET/CT. Osteolytic/sclerotic lesions matching FDG-avid foci were visible on the CT part of PET/CT in three patients. MRI ordered in three other patients suggested bone marrow involvement. Interim and/or end-therapy 18F-FDG PET/CT documented response of FDG-avid bone/bone marrow foci to chemotherapy in every patient.

Conclusion

18F-FDG PET/CT highly improves sensitivity for diagnosis of bone/bone marrow lesions in HL compared to conventional staging.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Diehl V. Hodgkin’s disease–from pathology specimen to cure. N Engl J Med 2007;357(19):1968–71.

    Article  PubMed  CAS  Google Scholar 

  2. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer 1996;78(6):1293–9.

    Article  PubMed  CAS  Google Scholar 

  3. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616–23.

    Article  PubMed  CAS  Google Scholar 

  4. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20(1):221–30.

    Article  PubMed  Google Scholar 

  5. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141(1):3–13.

    Article  PubMed  Google Scholar 

  6. Eghbali H, Raemaekers J, Carde P, EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol Suppl 2005 Jul;(66):135–40.

  7. Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23(26):6400–8.

    Article  PubMed  CAS  Google Scholar 

  8. Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 2007;18 Suppl 9:ix71–9.

    Article  PubMed  Google Scholar 

  9. Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, Van’t Veer MB, Aleman BM, et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 2009;115(8):1680–91.

    Article  PubMed  Google Scholar 

  10. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971;31(11):1860–1.

    PubMed  CAS  Google Scholar 

  11. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7(11):1630–6. Erratum in: J Clin Oncol 1990 Sep;8(9):1602.

    PubMed  CAS  Google Scholar 

  12. Howell SJ, Grey M, Chang J, Morgenstern GR, Cowan RA, Deakin DP, et al. The value of bone marrow examination in the staging of Hodgkin’s lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002;119(2):408–11.

    Article  PubMed  Google Scholar 

  13. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, et al. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood 2005;105(5):1875–80.

    Article  PubMed  CAS  Google Scholar 

  14. Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, et al. Classical Hodgkin’s lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009;94(4):550–65.

    Article  PubMed  Google Scholar 

  15. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339(21):1506–14.

    Article  PubMed  CAS  Google Scholar 

  16. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115(2):272–8.

    Article  PubMed  CAS  Google Scholar 

  17. Weihrauch MR, Re D, Scheidhauer K, Ansén S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001;98(10):2930–4.

    Article  PubMed  CAS  Google Scholar 

  18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  19. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16(7):1160–8.

    Article  PubMed  CAS  Google Scholar 

  20. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  21. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107(11):2678–87.

    Article  PubMed  Google Scholar 

  22. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol 2006;17(8):1296–300.

    Article  PubMed  CAS  Google Scholar 

  23. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25(24):3746–52.

    Article  PubMed  CAS  Google Scholar 

  24. Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, et al. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J Clin Oncol 2009;27(26):4385–91.

    Article  PubMed  Google Scholar 

  25. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27(11):1906–14.

    Article  PubMed  Google Scholar 

  26. Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 2006;91(4):482–9.

    PubMed  Google Scholar 

  27. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008;88(2):202–10.

    Article  PubMed  Google Scholar 

  28. Townsend DW. Positron emission tomography/computed tomography. Semin Nucl Med 2008;38(3):152–66.

    Article  PubMed  Google Scholar 

  29. Fend F, Kremer M. Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology 2007;74(2):133–43.

    Article  PubMed  Google Scholar 

  30. Kwee TC, Kwee RM, Verdonck LF, Bierings MB, Nievelstein RA. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol 2008;141(1):60–8.

    Article  PubMed  Google Scholar 

  31. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24(3):146–50.

    Article  PubMed  CAS  Google Scholar 

  32. Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9(1):15–27.

    Article  PubMed  CAS  Google Scholar 

  33. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin’ disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1995;13(2):403–9.

    PubMed  CAS  Google Scholar 

  34. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 1975;82(3):365–6.

    PubMed  CAS  Google Scholar 

  35. Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94(5):1522–31.

    Article  PubMed  Google Scholar 

  36. Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91(9):3340–6.

    PubMed  CAS  Google Scholar 

  37. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46(6):958–63.

    PubMed  Google Scholar 

  38. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006;259–65:510–1.

    Google Scholar 

  39. Bain BJ. Bone marrow biopsy morbidity and mortality: 2002 data. Clin Lab Haematol 2004;26(5):315–8.

    Article  PubMed  CAS  Google Scholar 

  40. Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin’s disease. Ann Oncol 2004;15(11):1699–704.

    Article  PubMed  CAS  Google Scholar 

  41. Kabickova E, Sumerauer D, Cumlivska E, Drahokoupilova E, Nekolna M, Chanova M, et al. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin’s disease. Eur J Nucl Med Mol Imaging 2006;33(9):1025–31.

    Article  PubMed  Google Scholar 

  42. Rigacci L, Vitolo U, Nassi L, Merli F, Gallamini A, Pregno P, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007;86(12):897–903.

    Article  PubMed  Google Scholar 

  43. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, et al. FDG-PET in the detection of bone marrow disease in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52(1):9–16.

    PubMed  CAS  Google Scholar 

  44. Cerci JJ, Pracchia LF, Soares Junior J, Linardi Cda C, Meneghetti JC, Buccheri V. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil. Clinics (Sao Paulo) 2009;64:491–8.

    Google Scholar 

  45. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34(1):60–7.

    Article  PubMed  Google Scholar 

  46. Young CS, Young BL, Smith SM. Staging Hodgkin’s disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging 1998;1(3):161–4.

    Article  PubMed  Google Scholar 

  47. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16(2):603–9.

    PubMed  CAS  Google Scholar 

  48. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27(27):4548–54.

    Article  PubMed  Google Scholar 

  49. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007;357(19):1916–27.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Drs. Christian Gisselbrecht, Catherine Thieblemont, Patricia Franchi-Rezgui, Véronique Edline, Anne Vincent-Salomon, Jean Michon and all physicians and staff who participated in patient management at St-Louis Hospital and Institut Curie.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Service de Médicine Nucléaire, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris 7, 1, avenue Claude Vellefaux, 75475, Paris cedex 10, France

    Gerard Moulin-Romsee, Elif Hindié, Jean-Emmanuel Filmont & Jean-Luc Moretti

  2. Nuclear Medicine, Institut Curie, Paris, France

    Gerard Moulin-Romsee & Myriam Bénamor

  3. Haemato-Oncology, Hôpital Saint-Louis, Paris, France

    Xavier Cuenca, Pauline Brice & David Sibon

  4. Haematology, Institut Curie, Paris, France

    Didier Decaudin & Marcela Anitei

  5. Pathology, Hôpital Saint-Louis, Paris, France

    Josette Brière

  6. Radiology, Hôpital Saint-Louis, Paris, France

    Eric de Kerviler

Authors
  1. Gerard Moulin-Romsee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elif Hindié
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xavier Cuenca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pauline Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Didier Decaudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Myriam Bénamor
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Josette Brière
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marcela Anitei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Emmanuel Filmont
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Sibon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eric de Kerviler
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jean-Luc Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Hindié.

Additional information

Gerard Moulin-Romsee and Elif Hindié contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moulin-Romsee, G., Hindié, E., Cuenca, X. et al. 18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 37, 1095–1105 (2010). https://doi.org/10.1007/s00259-009-1377-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1377-5

Keywords

  • Hodgkin’s lymphoma
  • PET/CT
  • 18F-FDG
  • Bone marrow trephine biopsy
  • Staging